|
1
|
Ferlay J, Shin H, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Hessheimer AJ, Isabel Real M and
Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol
Hematol. 60:89–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyault S, Rickman DS, deReyniès A,
Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti
J, Franco D, et al: Transcriptome classification of HCC is related
to gene alterations and to new therapeutic targets. Hepatology.
45:42–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takigawa Y and Brown AM: Wnt signaling in
liver cancer. Curr Drug Targets. 9:1013–1024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Polakis P: The many ways of Wnt in cancer.
Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guigon CJ, Kim DW, Zhu X, Zhao L and Cheng
SY: Tumor suppressor action of liganded thyroid hormone receptor
beta by direct repression of beta-catenin gene expression.
Endocrinology. 151:5528–5536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Q, Dashwood WM, Zhong X, Al-Fageeh and
Dashwood RH: Cloning of the rat beta-catenin gene (Ctnnb1) promoter
and its functional analysis compared with the Catnb and CTNNB1
promoters. Genomics. 83:231–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu G, Jiang S, Wang C, et al: Zinc finger
transcription factor 191, directly binding to β-catenin promoter,
promotes cell proliferation of hepatocellular carcinoma.
Hepatology. 55:1830–1839. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Ye X, Zhang JB, et al: PROX1
promotes hepatocellular carcinoma proliferation and sorafenib
resistance by enhancing β-catenin expression and nuclear
translocation. Oncogene. 34:5524–5535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohamed MA, Greif PA, Diamond J, Sharaf O,
Maxwell P, Montironi R, Young RA and Hamilton PW: Epigenetic
events, remodelling enzymes and their relationship to chromatin
organization in prostatic intraepithelial neoplasia and prostatic
adenocarcinoma. BJU Int. 99:908–915. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stopka T and Skoultchi AI: The ISWI ATPase
Snf2h is required for early mouse development. Proc Natl Acad Sci
USA. 100:14097–14102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reisman D, Glaros S and Thompson EA: The
SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin Q, Mao X, Li B, Guan S, Yao F and Jin
F: Overexpression of SMARCA5 correlates with cell proliferation and
migration in breast cancer. Tumour Biol. 36:1895–1902. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stopka T, Zakova D, Fuchs O, Kubrova O,
Blafkova J, Jelinek J, Necas E and Zivny J: Chromatin remodeling
gene SMARCA5 is dysregulated in primitive hematopoietic cells of
acute leukemia. Leukemia. 14:1247–1252. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gigek CO, Lisboa LC, Leal MF, Silva PN,
Lima EM, Khayat AS, Assumpção PP, Burbano RR and Smith Mde A:
SMARCA5 methylation and expression in gastric cancer. Cancer
Invest. 29:162–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui J, Zhou X, Liu Y and Tang Z: Mutation
and overexpression of the beta-catenin gene may play an important
role in primary hepatocellular carcinoma among Chinese people. J
Cancer Res Clin Oncol. 127:577–581. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH,
Tsai FJ, Tsai CH, Weng YJ, Huang CY and Chen LM: β-catenin plays a
key role in metastasis of human hepatocellular carcinoma. Oncol
Rep. 26:415–422. 2011.PubMed/NCBI
|
|
20
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Chan TH, Yuan YF, et al: CHD1L
promotes hepatocellular carcinoma progression and metastasis in
mice and is associated with these processes in human patients. J
Clin Invest. 120:1178–1191. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Zhang JB, Qin Y, et al: PROX1
promotes hepatocellular carcinoma metastasis by way of
up-regulating hypoxia-inducible factor 1α expression and protein
stability. Hepatology. 58:692–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chuma M, Sakamoto M, Yasuda J, Fujii G,
Nakanishi K, Tsuchiya A, Ohta T, Asaka M and Hirohashi S:
Overexpression of cortactin is involved in motility and metastasis
of hepatocellular carcinoma. J Hepatol. 41:629–636. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lau SH, Sham JS, Xie D, Tzang CH, Tang D,
Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, et al: Clusterin
plays an important role in hepatocellular carcinoma metastasis.
Oncogene. 25:1242–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun CK, Ng KT, Sun BS, Ho JW, Lee TK, Ng
I, Poon RT, Lo CM, Liu CL, Man K and Fan ST: The significance of
proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma
progression and recurrence. Br J Cancer. 97:50–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tung-Ping Poon R, Fan ST and Wong J: Risk
factors, prevention, and management of postoperative recurrence
after resection of hepatocellular carcinoma. Ann Surg. 232:10–24.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y,
Li L and Shen P: Estrogen represses hepatocellular carcinoma (HCC)
growth via inhibiting alternative activation of tumor-associated
macrophages (TAMs). J Biol Chem. 287:40140–40149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang WL, Wei L, Huang WQ, Li R, Shen WY,
Liu JY, Xu JM, Li B and Qin Y: Vigilin is overexpressed in
hepatocellular carcinoma and is required for HCC cell proliferation
and tumor growth. Oncol Rep. 31:2328–2334. 2014.PubMed/NCBI
|
|
30
|
Jiang YF, Yang ZH and Hu JQ: Recurrence or
metastasis of HCC: Predictors, early detection and experimental
antiangiogenic therapy. World J Gastroenterol. 6:61–65. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmidt-Ott KM and Barasch J:
WNT/beta-catenin signaling in nephron progenitors and their
epithelial progeny. Kidney Int. 74:1004–1008. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Corona DF, Längst G, Clapier CR, Bonte EJ,
Ferrari S, Tamkun JW and Becker PB: ISWI is an ATP-dependent
nucleosome remodeling factor. Mol Cell. 3:239–245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
VargaWeisz PD and Becker PB:
Chromatin-remodeling factors: Machines that regulate? Curr Opin
Cell Biol. 10:346–353. 1998. View Article : Google Scholar : PubMed/NCBI
|
